Skip to content
Yog Pharma
CardiovascularP2Y12 platelet inhibitor

Clopidogrel Bisulfate is a P2Y12 platelet inhibitor indicated for reduction of thrombotic events after acute coronary syndrome, recent myocardial infarction, stroke or peripheral arterial disease. We supply it to US manufacturers of tablets.

CAS120202-66-6419.9 g/molC16H18ClNO6S2
2D structure of Clopidogrel Bisulfate, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 115366) and FDA’s substance registry

CAS number

120202-66-6

Molecular formula

C16H18ClNO6S2

Molecular weight

419.9g/mol

FDA UNII

IUPAC name

methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric acid

InChIKey

FDEODCTUSIWGLK-RSAXXLAASA-N

Appearance
White to off-white powder.
Solubility
Practically insoluble in water at neutral pH and freely soluble at pH 1.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Exists as polymorphic Forms I and II, and sources hold separate filings for each. State the form, and check the limit for the inactive R-enantiomer.

On the US market

Reference product
PlavixNDA 020839
Approved ANDAs
16 with a marketed product
Approved forms and strengths
  • Tablet 75 mg, 300 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com